EMA Authorised: Saphnelo (anifrolumab) — AstraZeneca AB

View source ↗

Summary

EMA has authorised Saphnelo (anifrolumab) for systemic lupus erythematosus in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Status: Authorised. Therapeutic area: Lupus Erythematosus, Systemic. MAH: AstraZeneca AB. Decision date: 09/07/2026